<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38874226</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Risks of cutaneous immune-related adverse events in long COVID: Multinational cohort studies in South Korea, Japan, and the UK.</ArticleTitle><Pagination><StartPage>e29740</StartPage><MedlinePgn>e29740</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29740</ELocationID><Abstract><AbstractText>Previous research has not investigated the persistent cutaneous immune-related adverse events (cirAEs) related to long COVID to investigate the long-term sequelae. This multinational study, using a propensity-matched overlap weighting method, utilizes large national claims-based cohorts, using ICD-10 code diagnosis, focusing on patients aged &#x2265;20 years from three countries: South Korean, Japanese, and the British cohorts. To estimate the risk of cirAEs in long COVID, the persistence or emergence of cirAEs occurring 4 weeks after the initial SARS-CoV-2 infection, we employed a Cox proportional hazard regression model. The Korean cohort (n&#x2009;=&#x2009;5,937,373; mean age 49.2 years [SD: 13.2]), the Japanese cohort (n&#x2009;=&#x2009;4,307,587; 42.5 years [13.6]), and the UK cohort (n&#x2009;=&#x2009;395,435; 71.0 years [8.07]) were presented. An increased risk of cirAEs in long COVID was observed (HR, 1.10; 95% CI, 1.06-1.14) in Korean cohort, while a similar association was observed in Japanese and UK cohorts. The long-term risk of cirAEs in long COVID was higher in more severe COVID-19 cases (1.31; 1.22-1.39). Unlike the increased risk of cirAEs in long COVID, COVID-19 vaccination attenuated the risk, especially with two or more doses (1.03; 0.95-1.11) or heterologous regimens (0.98; 0.76-1.27). The time attenuation effect indicated a sustained risk for up to 6 months postinfection (&lt;3 months: 1.13 [1.07-1.19]; 3-6 months: 1.14 [1.06-1.22]). SARS-CoV-2 infection is associated with an increased risk of cirAEs in the aspect of long COVID. Vaccination might reduce this risk, highlighting the need for preventive strategies in long COVID management.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyejun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Applied Information Engineering, Yonsei University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kyung</LastName><ForeName>Seoyeon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Jaeyu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hojae</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Myeongcheol</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Centre for Health, Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahmati</LastName><ForeName>Masoud</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4792-027X</Identifier><AffiliationInfo><Affiliation>Department of Physical Education and Sport Sciences, Faculty of Literature and Human Sciences, Lorestan University, Khoramabad, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Education and Sport Sciences, Faculty of Literature and Humanities, Vali-E-Asr University of Rafsanjan, Rafsanjan, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Assistance Publique-H&#xf4;pitaux de Marseille (APHM), CEReSS-Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ju-Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jiseung</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Sleep Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Louis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research and Development Unit, Parc Sanitari Sant Joan de D&#xe9;u, CIBERSAM, ISCIII, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Lariboisi&#xe8;re-Fernand Widal Hospital, AP-HP, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology of Ageing and Neurodegenerative Diseases (EpiAgeing), Inserm U1153, Universit&#xe9; Paris Cit&#xe9;, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>Nikolaos G</ForeName><Initials>NG</Initials><AffiliationInfo><Affiliation>Allergy Department, 2nd Paediatric Clinic, National and Kapodistrian University of Athens, Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Sang Youl</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jinseok</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Kyung Hee University College of Electronics and Information, Yongin, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyeon Jin</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hayeon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Kyung Hee University College of Electronics and Information, Yongin, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yon</LastName><ForeName>Dong Keon</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0003-1628-9948</Identifier><AffiliationInfo><Affiliation>Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Kyung Hee University College of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>National Research Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012871" MajorTopicYN="N">Skin Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">cirAEs</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">multi&#x2010;national</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>14</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>14</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>14</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38874226</ArticleId><ArticleId IdType="doi">10.1002/jmv.29740</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus&#x2010;2 (SARS&#x2010;CoV&#x2010;2): a global pandemic and treatment strategies. Int J Antimicro Ag. 2020;56(2):106054.</Citation></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nature Med. 2021;27(4):601&#x2010;615.</Citation></Reference><Reference><Citation>Hinterseher J, Hertl M, Didona D. Autoimmune skin disorders and SARS&#x2010;CoV&#x2010;2 vaccination&#x2014;a meta&#x2010;analysis. J Dtsch Dermatol Ges. 2023;21(8):853&#x2010;861.</Citation></Reference><Reference><Citation>Martora F, Picone V, Fornaro L, Fabbrocini G, Marasca C. Can COVID&#x2010;19 cause atypical forms of pityriasis rosea refractory to conventional therapies? J Med Virol. 2022;94(4):1292&#x2010;1293.</Citation></Reference><Reference><Citation>Martora F, Fabbrocini G, Marasca C. Pityriasis rosea after moderna mRNA&#x2010;1273 vaccine: a case series. Dermatol Ther. 2022;35(2):e15225.</Citation></Reference><Reference><Citation>Picone V, Fabbrocini G, Martora L, Martora F. A case of new&#x2010;onset Lichen Planus after COVID&#x2010;19 vaccination. Dermatol Ther. 2022;12(3):801&#x2010;805.</Citation></Reference><Reference><Citation>Chen W, Wan G, Nguyen N, et al. Identification of cutaneous immune&#x2010;related adverse events by international classification of diseases codes and medication administration. JAAD Int. 2022;9:112&#x2010;115.</Citation></Reference><Reference><Citation>Ren J, Pang W, Luo Y, et al. Impact of allergic rhinitis and asthma on COVID&#x2010;19 infection, hospitalization, and mortality. J Allergy Clin Immunol Pract. 2022;10(1):124&#x2010;133.</Citation></Reference><Reference><Citation>Peng K, Li X, Yang D, et al. Risk of autoimmune diseases following COVID&#x2010;19 and the potential protective effect from vaccination: a population&#x2010;based cohort study. eClinicalMedicine. 2023;63:102154.</Citation></Reference><Reference><Citation>Shin YH, Shin JI, Moon SY, et al. Autoimmune inflammatory rheumatic diseases and COVID&#x2010;19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol. 2021;3(10):e698&#x2010;e706.</Citation></Reference><Reference><Citation>Kyung S, Son Y, Kim M, et al. Risks of alopecia areata in long COVID: binational population&#x2010;based cohort studies from South Korea and Japan. J Med Virol. 2024;96(5):e29668.</Citation></Reference><Reference><Citation>Oh J, Lee M, Kim M, et al. Incident allergic diseases in post&#x2010;COVID&#x2010;19 condition: multinational cohort studies from South Korea, Japan and the UK. Nat Commun. 2024;15(1):2830.</Citation></Reference><Reference><Citation>Kim MS, Lee H, Lee SW, et al. Long&#x2010;term autoimmune inflammatory rheumatic outcomes of COVID&#x2010;19: a binational cohort study. Ann Intern Med. 2024;177(3):291&#x2010;302.</Citation></Reference><Reference><Citation>Noh Y, Jeong HE, Choi A, et al. Prenatal and infant exposure to acid&#x2010;suppressive medications and risk of allergic diseases in children. JAMA Pediatrics. 2023;177(3):267&#x2010;277.</Citation></Reference><Reference><Citation>Lee SW, Lee J, Moon SY, et al. Physical activity and the risk of SARS&#x2010;CoV&#x2010;2 infection, severe COVID&#x2010;19 illness and COVID&#x2010;19 related mortality in South Korea: a nationwide cohort study. Br J Sports Med. 2022;56(16):901&#x2010;912.</Citation></Reference><Reference><Citation>Lee SW, Yang JM, Moon SY, et al. Association between mental illness and COVID&#x2010;19 in South Korea: a post&#x2010;hoc analysis. Lancet Psychiatry. 2021;8(4):271&#x2010;272.</Citation></Reference><Reference><Citation>Lee SW, Yang JM, Moon SY, et al. Association between mental illness and COVID&#x2010;19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study. Lancet Psychiatry. 2020;7(12):1025&#x2010;1031.</Citation></Reference><Reference><Citation>Thompson LL, Yoon J, Krasnow NA, et al. Association between systemic corticosteroid treatment for cutaneous immune&#x2010;related adverse events and survival outcomes in patients with advanced cancer. JAMA Dermatology. 2021;157(5):599&#x2010;602.</Citation></Reference><Reference><Citation>Zhang YB, Chen C, Pan XF, et al. Associations of healthy lifestyle and socioeconomic status with mortality and incident cardiovascular disease: two prospective cohort studies. BMJ. 2021;373:n604.</Citation></Reference><Reference><Citation>Oseran AS, Song Y, Xu J, et al. Long term risk of death and readmission after hospital admission with covid&#x2010;19 among older adults: retrospective cohort study. BMJ. 2023;382:e076222.</Citation></Reference><Reference><Citation>Brodin P. Immune determinants of COVID&#x2010;19 disease presentation and severity. Nature Med. 2021;27(1):28&#x2010;33.</Citation></Reference><Reference><Citation>Patrick MT, Zhang H, Wasikowski R, et al. Associations between COVID&#x2010;19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol. 2021;147(3):857&#x2010;869.e7.</Citation></Reference><Reference><Citation>Lam ICH, Wong CKH, Zhang R, et al. Long&#x2010;term post&#x2010;acute sequelae of COVID&#x2010;19 infection: a retrospective, multi&#x2010;database cohort study in Hong Kong and the UK. eClinicalMedicine. 2023;60:102000.</Citation></Reference><Reference><Citation>Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID&#x2010;19: an evidence&#x2010;based review. Am J Clin Dermatol. 2020;21(5):627&#x2010;639.</Citation></Reference><Reference><Citation>Fowler J, Jarratt M, Moore A, et al. Once&#x2010;daily topical brimonidine tartrate gel 0&#xb7;5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle&#x2010;controlled studies. Br J Dermatol. 2012;166(3):633&#x2010;641.</Citation></Reference><Reference><Citation>Elias J, Boss E, Kaplan A. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of t&#x2010;lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol. 1986;78(5):914&#x2010;918.</Citation></Reference><Reference><Citation>Kim BS. The translational revolution of itch. Neuron. 2022;110(14):2209&#x2010;2214.</Citation></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID&#x2010;19. Nat Rev Rheumatol. 2020;16(8):413&#x2010;414.</Citation></Reference><Reference><Citation>Gudjonsson JE, Kabashima K, Eyerich K. Mechanisms of skin autoimmunity: cellular and soluble immune components of the skin. J Allergy Clin Immunol. 2020;146(1):8&#x2010;16.</Citation></Reference><Reference><Citation>Hwang J, Park SH, Lee SW, et al. Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID&#x2010;19 vaccination: the FAPIC score. Eur Heart J. 2021;42(39):4053&#x2010;4063.</Citation></Reference><Reference><Citation>Lee SW, Kim SY, Moon SY, et al. Estimating COVID&#x2010;19 infection and severity risks inpatients with chronic rhinosinusitis: a Korean nationwide cohort study. J Allergy Clin Immunol Pract. 2021;9(6):2262&#x2010;2271.e2.</Citation></Reference><Reference><Citation>Sharma C, Bayry J. High risk of autoimmune diseases after COVID&#x2010;19. Nat Rev Rheumatol. 2023;19(7):399&#x2010;400.</Citation></Reference><Reference><Citation>Stein SR, Ramelli SC, Grazioli A, et al. SARS&#x2010;CoV&#x2010;2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758&#x2010;763.</Citation></Reference><Reference><Citation>Hou HS, Bonku EM, Zhai R, et al. Extraction of essential oil from Citrus reticulate Blanco peel and its antibacterial activity against cutibacterium acnes (formerly Propionibacterium acnes). Heliyon. 2019;5(12):e02947.</Citation></Reference><Reference><Citation>Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID&#x2010;19. Signal Transduct Target Ther. 2021;6(1):255.</Citation></Reference><Reference><Citation>Del Valle DM, Kim&#x2010;Schulze S, Huang H&#x2010;H, et al. An inflammatory cytokine signature predicts COVID&#x2010;19 severity and survival. Nature Med. 2020;26(10):1636&#x2010;1643.</Citation></Reference><Reference><Citation>Lelis F, Byk LA, Pustylnikov S, et al. Safety, immunogenicity and efficacy of an mRNA&#x2010;based COVID&#x2010;19 vaccine, GLB&#x2010;COV2&#x2010;043, in preclinical animal models. Sci Rep. 2023;13(1):21172.</Citation></Reference><Reference><Citation>Liu Y, Sawalha AH, Lu Q. COVID&#x2010;19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155&#x2010;162.</Citation></Reference><Reference><Citation>Kobayashi T, Naik S, Nagao K. Choreographing immunity in the skin epithelial barrier. Immunity. 2019;50(3):552&#x2010;565.</Citation></Reference><Reference><Citation>Bollyky TJ, Castro E, Aravkin AY, et al. Assessing COVID&#x2010;19 pandemic policies and behaviours and their economic and educational trade&#x2010;offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis. Lancet. 2023;401(10385):1341&#x2010;1360.</Citation></Reference><Reference><Citation>Lison A, Banholzer N, Sharma M, et al. Effectiveness assessment of non&#x2010;pharmaceutical interventions: lessons learned from the COVID&#x2010;19 pandemic. Lancet Public Health. 2023;8(4):e311&#x2010;e317.</Citation></Reference><Reference><Citation>Lakhani CM, Tierney BT, Manrai AK, Yang J, Visscher PM, Patel CJ. Repurposing large health insurance claims data to estimate genetic and environmental contributions in 560 phenotypes. Nature Genet. 2019;51(2):327&#x2010;334.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>